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Background: Proteomics Signature Profiling (PSP) is a novel hit-rate based method that proved useful in resolving
consistency and coverage issues in proteomics. As a follow-up study, several points need to be addressed: 1/ PSP’s
generalisability to pathways, 2/ understanding the biological interplay between significant complexes and pathway
subnets co-located on the same pathways on our liver cancer dataset, 3/ understanding PSP’s false positive rate
and 4/ demonstrating that PSP works on other suitable proteomics datasets as well as expanding PSP’s analytical
resolution via the use of specialised ontologies.
Results: 1/ PSP performs well with Pathway-Derived Subnets (PDSs). Comparing the performance of PDSs derived
from various pathway databases, we find that an integrative approach is best for optimising analytical resolution.
Feature selection also confirms that significant PDSs are closely connected to the cancer phenotype.
2/ In liver cancer, correlation studies of significant PSP complexes and PDSs co-localised on the same pathways
revealed an interesting relationship between the purine metabolism pathway and two other complexes involved in
DNA repair. Our work suggests progression to poor stage requires additional mutations that disrupt DNA repair
enzymes.
3/ False positive analysis reveals that PSP, applied on both complexes and PDSs, is powerful and precise.
4/ Via an expert-curated lipid ontology, we uncovered several interesting lipid-associated complexes that could be
associated with cancer progression. Of particular interest is the HMGB1-HMGB2-HSC70-ERP60-GAPDH complex
which is also involved in DNA repair. We also demonstrated generalisability of PSP using a non-small-cell lung
carcinoma data set.
Conclusions: PSP is a powerful and precise technique, capable of identifying biologically coherent features. It works
with biological complexes, network-predicted clusters as well as PDSs. Here, an instance of the interplay between
significant PDSs and complexes, possibly significantly involved in liver cancer progression but not well understood
as yet, is demonstrated. Also demonstrated is the enhancement of PSP’s analytical resolution using specialised
ontologies.* Correspondence: wongls@comp.nus.edu.sg
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Proteomics Signature Profiling (PSP) is a novel method for
overcoming small sample size, consistency and coverage
issues in proteomics [1]. The underlying idea for this
method is, despite the lack of consistency in reported pro-
teins, detection is nonetheless context-dependent (the said
context being components of conserved and implicated
biological complexes or biological pathways) and therefore
could be informative if exploited appropriately.
This idea was tested in a published study of Hepatocel-
lular Carcinoma (HCC) patients (5 in moderate and 7 in
poor stage) [2]. Utilising real and predicted protein com-
plexes, it is possible to strongly recover patient subclasses
in agreement with histopathology. Feature selection also
identified liver cancer-associated complexes involved in
apoptosis, cell cycle regulation, etc.
It is remarkable this is achievable in spite of little inter-
patient agreement. To highlight this, in mod-stage
patients, only 25 out of over 800 proteins are common to
all 5 patients. Of these 25, all are also reported in poor-
stage patients with relatively high counts (≥ 4 out of 7
patients) with the exception of HSP90AA2 and TRAP1
(≤ 2 out of 7 patients). In poor stage, only 3 out of over
1000 proteins are common to all 7. Of these, 2 (CLU and
CSTB) are reported in mod-stage patients. LYZ or lyso-
zyme, is the only detected protein common to all 7 poor
patients and not found in mod-stage patients. The large
disparities between reported proteins meant that it was
difficult to select potential biomarkers, and also not pos-
sible to generate meaningful hierarchical clustering based
on detected proteins. Additional file 1: Figure S1 high-
lights the extent of poor analytical resolution if hierarch-
ical clustering is performed on the data as it is; the
underlying patient classes cannot be recovered.
As a follow-up study, we identified four essential
points to address: Firstly, we show that pathways can
also be used with the PSP approach. While complexes
provided a biologically-rich feature set, it is limited.
Pathways are also suitable networks on which PSP
could be utilised but has several caveats. 1/ Size and
topology: Individual pathways vary considerably in
size. Suppose that only a small portion of a large
pathway is involved, standard statistical tests would
fail. 2/ Coverage and consistency issues: Current path-
way databases have abysmal agreement even on the
most well-studied pathways. We recently developed
an integrated pathway database, PathwayAPI [3],
which utilises a novel pathway merging approach
based on pathway name matches (Longest Common
Substring matching; LCS) [3]. However, the value of
this integration has never been demonstrated in a
functional study. Furthermore, it is not known how
using individual pathway databases—e.g., KEGG or
IPA—would affect or skew analysis.Secondly, as pathways are large biological entities with
specialised processes, significant PSP-derived complexes
and PDSs that co-locate on the same biological path-
ways, might engage in novel interplays that may account
for cancer progression. This is worth examining further.
Thirdly, the actual false positive rate needs to be better
understood, as it was not studied in the original paper.
As PSP uses all detected proteins, the possibility of high
false positive rates could be a concern. While we demon-
strated theoretically in the PSP paper why false positives
are negated, we did not show in actual terms its severity
or negligibility.
The fourth aim of this study is to demonstrate PSP’s
generalisability and to enhance its analytical resolution
using specialised ontologies. On the latter, many func-
tional studies are reliant on, but also limited by, the analyt-
ical resolution of Gene Ontology (GO). GO was developed
for general purposes and, on its own, might not yield spe-
cialised/advanced insights especially when a specific bio-
logical context—e.g., cancer—is being considered. Here,
we use a lipid ontology based on GO for uncovering novel
lipid-associated complexes implicated in liver cancer pro-
gression. On generalisability, we demonstrate that PSP
also works in a non-small-cell lung carcinoma (NSCLC)
dataset comparing two subtypes, adenocarcinoma (ADC)
and squamous cell carcinoma (SCC).Results and discussions
Significant PDSs are involved with cancer-associated
functionalities
A PDS is a pathway-derived and biologically coherent fea-
ture determined by the proteomics data. It is a connected
subnet within a biological pathway, which is more likely to
function together based on the expression data (See meth-
ods for details). There are a number of prior works on
extracting subnetworks from (large) interaction databases,
e.g., Ideker et al. [4] and Rajagopalan and Agarwal [5].
While it may also be possible to adapt these other subnet-
work methods for extracting PDSs, we feel it is probably
best left to a separate (preferably, independently con-
ducted) comparative study. Here, we focus instead on a
proof-of-concept to demonstrate that subnets extracted
from pathways also work with the PSP approach.
From PathwayAPI, 87 PDSs are derived from the non-
merged pathways (derived from 75 different pathways;
Additional file 2: Table S1), of which, 23 belong to path-
ways merge-able in PathwayAPI via LCS. The PDSs are
of reasonable sizes, about 70% are size 10 and above
(Additional file 3: Figure S2). There does not appear to
be a bias for any particular pathway, with most pathways
contributing just one and in some rarer cases, two PDSs;
see Additional file 2: Table S1.
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GO terms for each of these PDSs are identified. We are
also interested in the proportional representation of the
significant GO terms across all significant PDSs
(Additional file 4: Table S3). Unsurprisingly, many of the
PDSs are associated with metabolism; Figure 1C. However,
we also observed a good number of significant PDSsFigure 1 Analytical pipeline, clustering results and GO term distributi
used to build PDSs (Pathway-Derived Subnets) from an integrated pathway
for each patient to generate a PSP. The set of PSPs are used for sample cla
analysis PDSs have sufficient resolution to segregate mod- and poor-stage
large number of significant GO terms are associated with metabolic functio
immune responses are also uncovered. This is consistent with earlier obserinvolved in deregulated metabolism, unstable DNA, cellu-
lar proliferation and self-sufficiency in growth signals, in-
flammation and immunity, angiogenesis, metastasis and
invasiveness, and avoiding cell death. To emphasize how
the terms are related to cancer, the significant GO terms
are further arranged in terms of the major cancer hall-
marks [6]; see Additional file 5: Table S4.ons. A: Detected proteins in mod- and poor-stage HCC patients are
database (PathwayAPI). These PDSs are used for calculating hit rates
ss analysis as well as significant feature identification. B: Sample class
patients with high confidence. C: Significant GO term distribution A
ns. Although cancer-associated terms such as apoptosis, growth and
vations based on this dataset.
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While Soh et al. [3] showed that pathway merging via
string name matching (LCS) is a more robust approach
than based on gene and gene interaction overlaps, the ef-
fect of this merging method is not known in any sort of
functional analysis. We would like to understand how this
integration affects analysis.
Extracting subnets from merged PathwayAPI data
returned 82 PDSs. The small drop of 5 PDSs (from 87)
suggests that merging the pathways (based on the LCS ap-
proach) did not make any major change to the overall
results. But since slightly less PDSs are produced for
merged pathways, they must have been merged into the
other PDSs. Suppose PDSx (among the 5 absorbed PDSs)
got merged with PDSy (among the remaining PDSs) in
some merged pathway P. This must mean that PDSx and
PDSy hit two different parts of P that were not contiguous
in the un-merged source pathways Px and Py of P. But Px
and Py got connected in P after merging.
Clustering of the 87 PDSs from non-merged PathwayAPI
did reveal they are also capable of segregating the patients
into their respective subclasses with high confidence
(AU score = 100). The red and green numbers refer to the
AU (Approximately Unbiased) and BP (Bootstrap Probabil-
ity) p-values (between 0 and 100) respectively. Higher
values denote higher confidence. Red squares indicate lar-
gest possible clusters where the AU p-value is above 95.
Additionally, mod patient 203, which was previously found
to be anomalous, was once again found in the poor-stage
cluster (Figure 1B).
Clustering the 82 PDSs from merged PathwayAPI recov-
ered the same tree topology. However, the AU score
dipped slightly to 99. While the PDSs and significant
biological complexes from PSP are vastly different, the
topology of the clustering tree is essentially similar, with
strong segregation of both mod and poor class patients;
Additional file 6: Figure S3.
These results suggest that the LCS merging procedure
in PathwayAPI does maintain the integrity of pathway
information. But beyond this automated approach, more
needs be done, e.g., manual/expert curation to ensure
functional congruity and data quality. After all, pathways
are very intricately joined, and contain many common
members/edges (which also causes the problem with
data integration in pathway databases). To illustrate this
point, a network was built based on taking a naïve union
of all existing pathways in PathwayAPI. There were no
isolated components in this highly inter-connected sys-
tem making it difficult to disambiguate the various con-
stituent pathways. More importantly, attempting to
extract PDSs from this results in one super component
of size 350, and 3 components of sizes 4, 4 and 6. This
lack of informative network features confounds the PSP
profiling approach.Comparative analysis between PathwayAPI and its
constituent databases
PathwayAPI (both merged based on the LCS approach
and non-merged) outperforms its constituent databases,
demonstrating the value of integration (Additional file 6:
Figure S3). Of the constituent databases, KEGG performs
slightly worse than PathwayAPI but the topology of the
tree is similar. Wiki performs second best: it keeps the
general order of the patients but does not have sufficient
information to reach significance in separating the patient
classes (threshold AU score ≥ 95). IPA is generally similar
to Wiki as well, but the mod 203 and poor 120 branch is
translocated to the mod group instead.
In any case, the two trees (IPA and Wiki) are of lower
confidence than KEGG’s, as well as those based on
PathwayAPI and real/predicted complexes. The reason for
this is due to the number of features (PDSs and significant
PDSs) contributed by each database. Altogether, 58 out of
87 PDSs reached significance at p ≤ 5%, indicating they
are strongly discriminative between mod and poor stages;
see Additional file 7: Table S2. The high proportion of sig-
nificant PDSs is because they are already pre-pruned to
just the pathway regions where variation between mod
and poor is expected to occur.
On the individual pathway databases, KEGG contributes
43 significant PDSs out of 65 PDSs derived from 172 path-
ways in KEGG, Wiki 6 significant PDSs out of 11 (82 path-
ways), and IPA 9 significant PDSs out of 11 (45 pathways)
respectively (to make a total of 58 significant out of 87
total PDSs (299 pathways) in PathwayAPI. Due to the
smaller number of resolving features (PDSs), it is not sur-
prising that Wiki and IPA perform poorer in their ability
to resolve the patient samples properly.
Given this result, we cannot over generalise on the re-
spective quality of the individual databases. But the key
implication here is that one should never defer to the
results from one database solely. Obviously, coverage dis-
crepancies between different databases can result in varia-
tions of analytical outcomes. It is thus best to refer to an
integrated data resource.
Significant PDSs and complexes are enriched for co-
location on pathways
We use the term “involved” to suggest that a pathway is
implicated in HCC if it gave rise to a signficant PDS.
There are a total of 159 significant PSP complexes
(i.e., biological complexes that are significantly differential
between mod and poor stage). The significant PDSs ori-
ginate from 58 different “involved” pathways. The number
of non-involved pathways is therefore 241 (299–58). On
the other hand, 20% (12 / 58) of the involved pathways
overlap with a significant complex while 11% (27 / 241) of
the non-involved pathways overlap with a significant com-
plex. Hence, an involved pathway is ~ 2x (20/11) more
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complex; Additional file 8: Table S5.
Also, none of the 364 (523–159) non-significant com-
plexes overlap with any of the 75 involved pathways, while
10 non-significant complexes overlap some of the 241
non-involved pathways. The propensity for significant
complexes to co-localise onto the same pathway with a
significant PDS is therefore notably high.
To show that the co-localisation effect is not due to the
effect of the same proteins being found on both the PSP
complexes and PDSs, we looked at the distribution of over-
laps between PDS and PSP complexes co-located on the
same pathway. In 70% of cases, the Jaccard Score (i.e., inter-
section over union) is much smaller than 0.2, indicating
that this was not due to the effect of the shared proteins.
A novel molecular switch implicated in HCC progression
The co-locating PDSs and PSP complexes (onto the same
pathway) should function in a coordinate manner (i.e., their
corresponding cluster scores/expression values should cor-
relate); and generally, this is true. The cluster score correla-
tions between co-located PDS and PSP complexes were
examined for both mod and poor stage; Figure 2. Although
the cluster scores are clearly correlated, this effect is more
pronounced in the poor stage (P = 0.0014, R-square = 0.47).
In the mod stage, the correlation is skewed by the pres-
ence of two outliers which are relatively high scoring in
PDS but low for complex. Removing the two outliers







































Figure 2 Left graph (red) shows absolute count distribution of false p
proportion (false positive features/total number of features). At 5% sig
frequency distributions is still rather high, implying internal clustering amon
proteins between poor stage liver cancer patients.regression fit (R-square) to 0.76 from 0.34. In poor stage,
both corresponding PDS and complexes are consistently
high.
We examined these two outliers, and found that they
corresponded to two different non-overlapping com-
plexes that co-locate on the same pathway (“Purine me-
tabolism”). In the mod stage, the scores for these two
complexes are low while the PDS is high. In the poor
stage, this disparity is negated: It is high in both PDS
and complex. It is possible that this is a switch mechan-
ism that may be involved in the progression from mod
to poor stage.
The major site of purine synthesis is in the liver.
Interestingly, it is known early on that enzymes involved
in purine metabolism play a role in cancer. In fact, an en-
zymic imbalance, specific only to liver cancer, was known
as early as 1983 [7]. However, the mechanistic details are
only recently being uncovered. Pang et al. [8] recently
showed that defects in purine metabolism leads to sub-
stantial incorporation of xanthine and hypoxanthine into
DNA. This in turn induces mutations, a key driver for
oncogenic progression.
We decide to investigate further by analysing the func-
tions of the co-localised complexes: “DNA synthesome
complex” and “TNF-alpha/NF-kappa B signaling complex
5”. The former is involved in fat signaling (GO:0048015
phosphatidylinositol-mediated signaling, P = 0.003), cellular
immortality (GO:0010833 telomere maintenance via telo-













































ositive features while right (purple) is the distribution of
nificance, the left shift of peaks is within expectation. However, the
g poor patients. This is expected given high variability of reported
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P = 0.048; GO:0006284 base-excision repair, P = 3.4e-10;
GO:0006283 transcription-coupled nucleotide-excision
repair, P = 5.0e-19) and cellular proliferation (GO:0000082
G1/S transition of mitotic cell cycle, P = 1.7e-12). The latter
is involved in stress/immune responses (GO:0045087
innate immune response, P = 1.7e-07; GO:0043123 positive
regulation of I-kappaB kinase/NF-kappaB cascade,
P = 2.4e-06), DNA repair (GO:0006283 transcription-
coupled nucleotide-excision repair, P = 0.002), cell death
(GO:0006916 anti-apoptosis, P = 0.005) and cellular prolif-
eration (GO:0000082 G1/S transition of mitotic cell cycle,
P = 0.02; GO:0016032 viral reproduction, P = 0.01). It is
clear that both complexes are involved in cancer-associated
functions, in particular, DNA repair.
The associated PDS appears to work primarily on
metabolic and purine-related functions, including
GO:0009161 ribonucleoside monophosphate metabolic
process (P = 0.0001) and GO:0006144 purine base meta-
bolic process (P = 7.9e-09). However, it is also related to
differentiation (GO:0002761 regulation of myeloid
leukocyte differentiation, P = 0.03) although myeloid dif-
ferentiation is typically associated with leukemias, not
with liver cancer.
Since the expression level of the PDS is both high in
mod and poor stage, it is possible that this is an early
requirement for oncogenic transformation. Indeed, up-
setting nitrogenous base balances can lead to increased
chance of error in DNA replications. Our identified
PDS suggests that this is the region of the purine
metabolism pathway most differentially affected. But in
order for oncogenic progression to occur or speed up
(for transition from mod- to poor-stage liver cancer), it
is logical, and indeed as we find, to target protein com-
plexes that are involved in rectifying mistakes in DNA
replication or effecting DNA repair. To further impli-
cate these two out of several other candidate DNA
repair complexes, they are closely associated with the
pathway as well. In light of these results, the biological
relationship between the purine metabolism PDS
and the associated PSP complexes should be further
explored experimentally.
PSP is a powerful and precise method with reasonably
low false positive rates
There are 523 biological complexes found in CORUM
(size ≥4) used in PSP. At p ≤ 5%, approximately 523 * 5%
≈ 27 false positives are expected. Similarly, there are 87
PDSs, and thus at p ≤ 5%, approximately 87 * 5% ≈ 5 false
positives are expected. In order to check the empirical
false positive rates against these theoretical estimates, we
used the 7 poor-stage patients, randomly assigned them
into two groups, and applied PSP analysis. Since both
groups were actually poor-stage patients, all significantcomplexes / PDSs resulting from this analysis should be
considered false positives.
Figure 3 shows the distribution of false positives across
10,000 randomisations for the poor-stage patients. In each
round, the set of significant complexes or PDSs (false posi-
tives) are reported at p ≤ 5% (with Benjamini-Hochberg
correction). Figure 3A and 3B shows the false positives
reported for CORUM (mean ≈ 80, median = 40, mode = 6)
and PathwayAPI (mean ≈ 18, median = 12, mode = 3)
respectively. The red bar shows the absolute false positive
counts while the purple bars are normalised to 1. The first
two peaks in Figure 3A and 3B are within expectation and
indicate a low false positive rate. However, the overall dis-
tribution of peaks, as well as the mean number of signifi-
cant clusters over 10,000 randomisations are slightly higher
than expected. This is likely due to the presence of internal
clusters among the poor-stage patients as well as small
sample size; Additional file 1: Figure S1.
While the false positive analysis may be more ideally
executed by using technical repeats from say, a cell line.
We nonetheless show here that these hit-rate based
methods utilising biological pathways and complexes are
powerful and precise.
Identification of novel lipid-associated complexes
involved in cancer progression
The liver is a major metabolic center, and a primary
regulation site of lipids. Current evidence suggest that
lipids are not mere energy-providing metabolites but can
effect profound changes via various signaling pathways.
This is not limited to cholesterol-based signaling mole-
cules, which are more well known. There are over 2,000
species of lipids, most of which have poor characterisa-
tion and not easily analysable [9]. Lipid dysregulation is
also commonly associated with liver cancer [10].
Many proteins are annotated to specific functionalities
based on GO annotation rules but the lipid associations
are not well known or sufficiently comprehensive.
To overcome this and to maximise compatibility with
current annotation standards, we developed a set of gold-
standard lipid-related terms based on GO terms; see
Methods. This list consists of 1463 lipid-associated GO
terms in the Biological Processing category (BP terms),
924 GO terms in the Cellular Component category
(CC terms) and 1736 GO terms in the Molecular Function
category (MF terms).
For BP, out of a total of 177 PSP predicted/real com-
plexes, 21 reached significance. Of these 21, 5 are pre-
dicted clusters. Therefore, about 12% of significant PSP
complexes are lipid associated. About half of these are not
previously known to be lipid associated . A list of these
novel/potentially novel BP lipid-associated real complexes
are reported in Table 1, and a full list (with further details)
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Figure 3 False positive distribution for PSP (A) and PDS (B). Co-localisation and expression profile of PDSs and complexes (DNA synthesome
and TNF-alpha/NF-kappa B signaling complex 5) on the purine metabolism pathway. A: The purine metabolic pathway is shown as an undirected
graph. Significant PSP clusters are highlighted in green while significant PDS is shown in purple. B and C: Regression plots for expression scores
of protein complexes and PDSs co-located on the same biological pathway in mod and poor stage respectively. Enveloped in a checked circle
are two complex outliers that are low expressing in the mod stage relative to the co-locating PDS but swung to overexpression in the poor
stage.
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HMGB1-HMGB2-HSC70-ERP60-GAPDH complex is of
particular interest. This complex was isolated from
human leukemia cells deficient in components of the
mismatch repair system (Nalm6) and functions by
detecting changes in DNA structure caused by incorpor-
ation of nonnatural nucleosides and is a determinant of
cell sensitivity to DNA modifying chemotherapy [11].
Disruption of DNA-repair mechanisms is important in
driving liver cancer progression from early to late stage
[12]. Moreover, this cluster exhibited a 2.5 fold increase
in expressional level. Its lipid involvement appears to be
dispersed however: It is involved in both golgi-mediated
transport and phosphoinositide-mediated signaling. Also
interesting are that the HMG family of proteins are asso-
ciated with malignant neoplasias [13], in particular,
HMGB1 was identified as a potential cancer therapeutic
target [14].
To understand if the other lipid GO categories also re-
port similar results, a similar analysis was repeated for
CC and MF terms, reporting 30 and 20 significant com-
plexes respectively.For the full list of complexes, refer to
Additional file 10: Table S7. Figure 4 shows the overlapsbetween the significant lipid-associated complexes derived
from each GO category. For MF and BP, more than
half of the complexes are shared with the other cat-
egories. For CC, this is slightly less than half. 8 signifi-
cant complexes are common to all three categories.
These include Retromer complex (comprising SNX1,
SNX2, VPS35, VPS29, VPS26B; involved in transport),
SNX complex (comprising SNX1,1a,2,4, PDGF receptor;
transport and signaling), SNX complex (comprising
SNX1a, SNX2, SNX4, TFRC; transport), RalBP1-
CCNB1-AP2A-NUMB-EPN1 complex (cell cycle), and
Retromer complex (comprising NX1, SNX2, VPS35,
VPS29, VPS26A; transport). The remaining 3 clusters
are predicted.
Although BP is commonly used for functional annota-
tion and analysis, the limited overlaps between the 3 cat-
egories suggest that it is prudent to examine all three
GO categories when determining lipid associations.
Generalisability using non-small-cell lung carcinoma
samples
To demonstrate generalisability, we performed similar
analysis using the results from Wei et al. [15]. Here, two
Table 1 List of potentially novel and novel lipid associated complexes implicated in liver cancer
Novelty CORUM
ID
Complex name Function Lipid involvement
PN 1096 SNX and PDGF receptor complex reported to be involved in transport and
transmembrane signal transduction
lipid involvement yes
PN 1104 Transferrin receptor complex reported involved in transport and receptor mediated
endocytosis
lipid association yes
PN 563 Complex V; F1F0 ATPase energy production, mitochondrial processes,
particularly in heart muscle
lipid involvement yes
PN 654 BLOC1-BLOC2 complex transport and targeting lipid involvement
potentially novel
PN 142 CD147-gamma-secretase complex (APH-1a,
PS-1, PEN-2, NCT variant)
signaling, protein fate lipid involvement yes
PN 652 AP3-Bloc1-complex transport lipid involvement yes
PN 657 Retromer complex (SNX1, SNX2, VPS35,
VPS29, VPS26A)
protein targeting and transport lipid involvement yes
PN 2837 Profilin 1 complex cytoskeleton organisation, endocytosis, potential
metastasis involvement
lipid involvement yes
PN 1060 Retromer complex (SNX1, SNX2, VPS35,
VPS29, VPS26B)
transport lipid association yes
N 280 HMGB1-HMGB2-HSC70-ERP60-GAPDH
complex
DNA repair, nucleic acid binding, response to stress




N 312 Cell cycle kinase complex CDK4l cell cycle control, cancer association yes lipid involvement not
immediately
decipherable





Signaling, cancer association yes lipid involvement not
immediately
decipherable
N 311 Cell cycle kinase complex CDK2 cell cycle control, cancer association yes lipid involvement not
immediately
decipherable
N 5423 HSP70-BAG5-PARK2 complex protein folding and stabilisation lipid involvement not
immediately
decipherable
N 2390 CD98-LAT2-ITGB1 complex cell adhesion, may define cell polarity which in turn




*PN – potentially novel, N – novel.
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adenocarcinoma (ADC) and squamous carcinoma (SCC)
were analyzed. We used the results from 2-dimensional
LC-MS/MS with multiplexed selective reaction monitor-
ing (SRM, or MRM). This dataset has less consistency
issues compared to the HCC dataset. As such, the
authors were able to analyse it using standard hierarch-
ical clustering.
However, there are variabilities, though limited, in
terms of identified proteins for each sample (n = 30). On
average, there are about 3000 identified proteins in total,
which is 3 times more than the HCC dataset.Figure 5A shows that the underlying patient subclasses
can be recovered with high confidence using complexes.
The estimated number of false positives (average = 19.93,
median =15, mode =12) for this was also within the
expected limit—523 complexes * 5% ≈ 27 false positives
are expected; Figure 5B. The left histogram shows the ab-
solute (Abs) count of significant clusters per randomisa-
tion. The right histogram is the number of significant
clusters normalised by the total number of randomisations
(ratio sig clusters).
Figure 5C shows the extent of protein support across










Figure 4 Overlaps between significant complexes identified via
lipid-associated GO BP, CC and MF terms. The overlaps between
significant lipid-associated clusters identified via lipid-associated GO
BP, CC and MF terms are expressed as a venn diagram. For all 3
categories, about at least half of the complexes are shared between
two categories.
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studied in PSP, the extent of variability is much reduced
here.
As mentioned earlier, the NSCLC dataset reported 3
times as many proteins than the HCC dataset. Since PSP is
dependent on variations in reported proteins per sample, it
may not work if the assay reports lots of proteins. However,
we find that the effectiveness of PSP is undiminished.
Current proteomics assays also saw the rise of exten-
sive set ups allowing reporting of more than 10,000 pro-
teins in samples [16,17]. However, these datasets are
incompatible with the PSP approach as the premise of
these are on deep proteome investigation of single cell
lines. PSP requires variability between samples, and in a
typical proteomics set up, achieving more than 10000
protein identifications is uncommon.Conclusions
PSP is a powerful and precise method, with acceptable
false positive rates. This is confirmed in the use of both
biological complexes as well as PDSs.
The PDSs are informative, being able to properly
recover the patient classes as well as selecting significant
features whose enriched GO terms are consistent with the
liver cancer phenotype.Pathway analysis based on integrated data is evidently
superior due to consistency and coverage issues among
databases. KEGG performs well with our data but the
added PDSs from WikiPathways and IPA improved ana-
lytical resolution.
By analysing the inter-play between co-localised signifi-
cant PDSs and complexes, we find very good expression
correlation implying coordinate responses and activity.
We also uncovered an interesting relationship for two
DNA repair complexes with the “purine metabolism”
pathway. This co-localisation appears to be involved in
mod-to-poor-stage liver cancer transition and warrants
further biological exploration. Finally, we also demonstrate
how analytical resolution can be enhanced via the use of
specialised ontologies. Specifically, we have identified
several novel lipid-associated complexes from the set of
significant PSP complexes.Methods
Data sources
Patient sample preparation and proteomics profiling
Briefly, liver tissues were obtained from 12 HCC-
diagnosed male patients with chronic Hepatitis B virus
(HBV) infection. Tissues collected were grouped accord-
ing to histology report; 5 had moderately differentiated
HCC (mod) and 7 had poorly differentiated HCC (poor).
Paired tissues were obtained from each patient, one from
the adjacent non-tumor region (normal) and the other
from the tumor region of the resected liver. Samples
were labelled with iTRAQ-tags and separated using two
phase LC-MS.
Proteomics analysis was performed using GPS Explorer
Ver. 3.6. Peptides and proteins were determined using
Paragon6 (Protein Pilot Ver. 4; AB SCIEX) and MASCOT5
(Ver. 2.1; Matrix Science) on IPI human database
(Ver. 3.31). Quantification of iTRAQ ratios and standard
deviation (s.d.) was performed using standard parameters
on GPS Explorer or Protein Pilot.
In Goh et al. [12], it was found that the reported pro-
teins from both databases (MASCOT and Paragon) corre-
sponded well in terms of ratios and ranks. Paragon is
more senstive than MASCOT and produced better results
in the original PSP paper. Hence in this work, only the
Paragon results are used. For details, refer to Additional
file 11: Supplementary Methods.
PathwayAPI
For the reference pathway database, we utilised Pathway
API [3], which comprised data from three major pathway
repositories: the Kyoto Encyclopedia of Genes and
Genomes (KEGG) [18], WikiPathways [19] and Ingenuity
Pathways (IPA) (www.ingenuity.com). It consists a total of











































































































































































































































































































Figure 5 Generalisability tests using NSCLC dataset. A: The underlying patient subclasses can be recovered with high confidence using
complexes. B: The left histogram shows the absolute (Abs) count of significant clusters per randomisation. The right histogram is the number of
significant clusters normalised by the total number of randomisations (ratio sig clusters). C: Protein support over 30 samples. Most proteins are
only supported by a subset of samples.
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As a whole pathways can be quite large, analytical reso-
lution can be enhanced by considering only the relevant
subnets. A PDS is a pathway-derived and biologically co-
herent subnet. To determine a PDS, detected proteins
found in at least half of the patients in mod and poor stage
respectively were mapped to each pathway. Expression fil-
ters (i.e., the levels of expression of the proteins) were not
used as they resulted in a very sparse number of small
subnets. Unmapped pathway proteins are removed, caus-
ing the pathway to fragment into connected components
or subnets. Subnets of minimum size 4 were extracted for
analysis as PDSs. The minimum size requirement reduces
large fluctuations in hit rates due to small sizes. The
derived PDSs are treated as a cluster vector of features.Clustering and feature selection
In the PSP paper [2], each feature C in the cluster vector
is a protein complex from the CORUM database. But here
PDSs are used instead. Given two sets A and B of prote-
omic profiles from two phenotypes respectively (mod andpoor), for each PDS C, and each patient i in A, the hit rate
HCAi, is defined as the overlap between the PDS C and
the proteins detected in patient i divided by the PDS size.
Similarly, we compute HCBj for each PDS C and patient j
in B. The total set of hit rates for each patient across the
set of PDSs is the patient’s signature profile.
These profiles are used to examine the consistency and
confidence of the derived relationships between samples.
For simplicity, hierarchical clustering was used to examine
sample relationships. Distances between individual profiles
were calculated using Euclidean, while Ward’s was used to
determine the clustering.
To evaluate confidence in the clustering results, the R
bootstrap resampling package pvclust was used. For the
tree generated, p-values (between 0 and 1) are calculated.
pvclust provides two types of p-values: AU (Approximately
Unbiased) and BP (Bootstrap Probability). AU, which is
computed by multiscale bootstrap resampling, is a better
approximation to unbiased p-value than BP value which is
computed by normal bootstrap resampling.
To perform feature selection, for each PDS C in the
cluster vector, two lists are produced HA = 〈HCA1,. . .,
Goh et al. BMC Genomics 2013, 14:35 Page 11 of 12
http://www.biomedcentral.com/1471-2164/14/35HCAm〉 and HB = 〈HCB1, . . .,HCBn〉, where A and B cor-
respond to the mod and poor stages. The t-statistic score
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If the t-statistic is significant, then the PDS C is differen-
tially expressed between the mod and poor stages. As the
calculated t-score may not necessarily follow a stand-
ard t-distribution, weighted randomisation via class
label swapping was performed between mod- and
poor-stage samples 10,000 times to produce the null
distribution. If the t-score value is negative (positive),
the empirical p-value is determined by the percentage
of null-distribution t-scores that are smaller (greater)
than the actual t-statistic value.
For those PDSs regarded as significant (p ≤ 5%), we
calculate a ranking score for the mod and poor stage re-
spectively using the reported iTRAQ protein ratios. Sup-
pose we have a PDS comprised of proteins A, B, C, D. A
is supported by 4 mod-stage patients with ratio (1.1, 0.8,
1, 1.2), B is supported by 1 patient with ratio of 5 while
C and D are not supported. If the ratio is lower than 1,
we convert it by taking its reciprocal. To find out how
big is this ratio, we take difference = ratio – 1. The
score, S, would thus be Σ(0.1, 1/0.8 - 1, 0, 0.2) + 4. How-
ever, with this scoring approach, PDSs with more pro-
teins tend to be ranked high. For example, a PDS with
10 proteins (A1, . . . , A10) and patient i has a high ratio
value on Ai and low ratio value on the other 9 proteins;
this PDS will get a higher score than a PDS of size 4
with all patients having medium ratio values on all 4
proteins in this PDS. To improve the scoring function
for such instances, we propose dividing S by the number
of unique proteins that were reported in the patient. For
example, suppose a PDS consists of proteins A, B, C, D,
there are 2 patients reporting A and their scores are 1.1,
1.2 while 1 patient report B and his score is 5. The clus-
ter score is (0.1 + 0.2 + 4)/2 (note that the denominator
is not 4).
False positive analysis for PDS and PSP
To determine whether the hit-rate based methods (PSP
and PDS) were reporting a large number of false positives,
poor-stage patients (being the larger group) were divided
into groups A and B randomly 10,000 times. A t-score,
and accompanying p-value were calculated as before.Gene ontology filtering and cluster functional annotation
GO provides a controlled vocabulary for assessing cluster
function and coherence. The annotation files and GO tree
files (ver. 1.2) for Homo sapiens, dated 23 April 2011,
were downloaded from http://www. geneontology.org.
UniProtKB accessions were mapped to Ensembl Gene IDs
via Biomart. To refine analysis, informative biological
process terms (term that is annotated to at least 30 pro-
teins and has no child term having more than 30 annotated
proteins) were extracted from the GO OBO file [20].
Significance testing was performed using hypergeometric
test with Bonferroni correction (p ≤ 5%).
Identification of novel lipid-associated complexes implicated
in liver cancer
Detailed curation rules for lipid-associated GO terms are
provided under Supplementary Methods. Briefly, for MF
and CC terms, it is based on indirect lipid-term and
functional associations. For BP terms, two principles,
criticality and generality are applied. The former is con-
cerned with identification of lipid-related key events, for
which no alternative steps are possible, while the latter
only holds if the association is generalisable across vari-
ous tissues or species.
The lipid association of a complex is the hit rate (a/n)
where a is the number of proteins (in the complex)
annotated to at least one lipid-related GO term, and n is
the size of the complex. We calculate the p-value using
a Functional Class Scoring (FCS)-like procedure [21]
where for each real cluster, we generate random clusters
of size n 10,000 times, and calculate a randomised lipid
content in a similar manner. The p-value is the number
of times a random lipid content for a randomised complex
is bigger than the original complex divided by total
number of randomisations.
Determination of a complex’s novelty is done manually
by searching for the presence of lipid-associated annota-
tions or references in the literature. A harder task how-
ever, is identifying which lipids are associated with the
protein complex. This is non-trivial as there are over 2,000
species of lipids, and many with unknown functions or
poor annotations.
Additional files
Additional file 1: Figure S1. Left: Histograms showing the lack of
consistency in identified proteins between patients in the same cancer
group (moderate and late). The hierarchical clustering tree on the right
demonstrates the poor resolving power of the proteomics data due to
lack of consistency, which justifies the need for novel approaches for
tackling this issue.
Additional file 2: Table S1. The contributions of each pathway to a
PDS. Pathway_ID correspond to the PathwayAPI pathway ID while
PDS_contribution indicates the number of PDSs that particular pathway
contribute based on the liver cancer proteomics dataset.
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http://www.biomedcentral.com/1471-2164/14/35Additional file 3: Figure S2. Size distribution of pathway subnets or
PDSs extracted from non-merged PathwayAPI using liver cancer proteomics
data. Most PDSs are relatively small, and range from size 5 to 10.
Additional file 4: Table S3. GO term distributions among significant PDSs.
Additional file 5: Table S4. Sorted significant GO terms according to
the cancer hallmark classifications.
Additional file 6: Figure S3. Clustered samples using HCL. Significance
is calculated the AU score. Significant clusters are enveloped in red
rectangles. The performance of clustering using different Pathway
databases are shown. Included also is the original clustering result from
PSP using biological (CORUM) and predicted complexes.
Additional file 7: Table S2. Set of 58 significant PDSs derived from
non-merged PathwayAPI. Shown also are the hit-rate p-values, expression
scores (mod and poor), constituent members and annotated GO terms.
Additional file 8: Table S5. Co-locating PDS and Complexes on same
biological pathways. Pathway_id corresponds to PathwayAPI’s reference
id. CORUM_id refers to CORUM databases’s index for biological complex.
Also included in this table are the constituent members, and expression
scores for PDSs and complexes for both mod and poor stage.
Additional file 9: Table S6. Predicted lipid-associated complexes.
Cluster_ID is the same as CORUM’s unless it is prefixed by a G, which
means it is a predicted cluster. The p-value is from PSP, which indicates
whether this cluster is significantly differential between mod and poor
groups. The lipid-content p-value denotes whether this cluster is
significantly lipid-associated. Mod and poor scores indicates the
expressional deregulation of the cluster in each cancer phase. Members
indicates the constitution of each cluster.
Additional file 10: Table S7. Significant clusters found for each GO
category for lipid association. Cluster_ID is the same as CORUM’s unless it
is prefixed by a G, which means it is a predicted cluster.
Additional file 11: Supplementary_Methods Details for the
proteomics experimental procedure.
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